Agfa submitted mdr report# 1225058-2010-00001 to the fda on june 7, 2010 for a site in the us.A 7th occurrence is being reported for the same issue/same device: impax cv results management administration tool (rmat).The customer, the initial reporter, in this new event contacted agfa on february 14, 2014 and reported a reading physician had discovered an incorrect statement in the pulmonary artery findings within their rmat reporting.The customer confirmed there were no reports of patient harm during this event.The customer stated no rmat customization requests had been made to agfa, and the site's super user had not made any custom changes to the pulmonary artery findings within the reporting tool, abiding by agfa's rmat terms of use.The customer described when reports were created for trans esophageal echocardiogram (tee), transthoracic echocardiogram (tte) and stress (str) studies, and when the end-user selected the "mild to moderate" radio button in the pulmonary artery pathology section, the incorrect sentence finding of "there is mild to moderate pulmonary hypotension" was generated in the report.The sentence finding should read "there is mild to moderate pulmonary hypertension." the same day the customer reported the event, agfa corrected the statement in both the test and production environments and; in turn, the customer reviewed the correction and confirmed the statement was reading correctly with "hypertension" versus "hypotension".Agfa confirmed rmat super user was disabled.
|